Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
March 28 2023 - 9:00AM
Business Wire
The New Assay Will Screen Patients for
Clinical Trials and Help Increase Data Analysis for Clinical
Researchers
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and a leader in data-driven medicine, today
announced that Acutis Diagnostics, a specialized medical
laboratory, will use SOPHiA DDM™ to develop a new genomic assay.
This new next-generation sequencing (NGS) test will build on Acutis
Diagnostics’ track record of approved lab-developed tests that
support clinical trials, cancer research and treatment.
To create the new assay, Acutis Diagnostics will pair SOPHiA
DDM™ for Hereditary Cancers Solution with their laboratory analysis
technologies. The test is in support of genomic screening for
patient enrollment in oncology clinical trials and for
retrospective analyses to help explain clinical outcomes and drug
target discovery.
“The use of SOPHiA DDM™ will help us quickly launch this new
assay to aid clinical researchers in speeding up the process for
launching select clinical oncology trials and ensuring the most
appropriate patients are enrolled,” said Dr. Abdel Halim, Chief
Scientific Officer and Executive Vice President, Acutis
Diagnostics. “Additionally, the test is to provide researchers with
a robust set of data and insights to support clinical
decision-making and future research.”
“Our work at SOPHiA GENETICS is focused on creating technology
and solutions that make it easier for everyone to practice and
benefit from data-driven medicine,” said Ken Freedman, Chief
Revenue Officer, SOPHiA GENETICS. “The new assay from Acutis
Diagnostics will be designed to enable clinical researchers to work
faster, and with a sound set of insights around their data,
ultimately benefitting their current and future patients, as well
as the industry as a whole.”
An estimated 20% of cancer patients have a family history of
cancer.1 Next-generation sequencing (NGS) is the technology of
choice in detecting biomarkers for hereditary cancers and
identifying mutations that help to inform treatment options. The
SOPHiA GENETICS hereditary cancer solutions are NGS-based
applications that use artificial intelligence and machine learning
with patented technologies to analyze raw NGS data and provide
simplified insights. This technology enables clinical researchers
to accurately characterize the complex mutational landscape
associated with major hereditary cancer disorders.
Through the use of SOPHiA GENETICS’ technology, the new assay
from Acutis Diagnostics is expected to further clinical research
and treatments for those who encounter hereditary cancers.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and
Instagram.
About SOPHiA GENETICS SOPHiA GENETICS (Nasdaq: SOPH) is a
cloud-native software company in the healthcare space dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad global network of hospitals, academic centers, laboratories
and biopharma institutions. For more information, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and
Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements: This press
release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products, and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management’s beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof. We expressly disclaim any obligation or undertaking to
update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
__________________________ 1 Al Harthi, F. S., et al. (2020)
‘Familial/inherited cancer syndrome: a focus on the highly
consanguineous Arab population’, npj Genomic Medicine, 5, 3
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230328005063/en/
Media: Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jul 2023 to Jul 2024